Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclin-T1 (CCNT1)
- Target
- CCNT1
- Molecular classification
- Cyclin, Transcription factor cofactor, Regulatory protein, Protein kinase regulator
01
Overview
Cyclin-T1 is a regulatory subunit of the **positive transcription elongation factor b (P-TEFb) complex**, predominantly partnering with the serine/threonine kinase CDK9. This complex is essential for the phosphorylation of the carboxy-terminal domain (CTD) of RNA polymerase II, enabling productive transcription elongation of most protein-coding genes. Cyclin-T1 is also crucial for the **transcriptional activation of HIV-1**, serving as a necessary cofactor for the HIV-1 Tat protein. The gene is part of the conserved cyclin family, which has important roles in cell cycle and transcriptional regulation. Overexpression or dysregulation may contribute to tumorigenesis or enhanced viral replication, and Cyclin-T1 is a focal point in studying antiviral and anticancer therapeutic interventions
- Other names
- Cyclin T1CCNT1CycT1Cyclin-TCCNTCYCT1HIVE1cyclin-T1CDK9-associated C-type proteinMLLT10/CCNT1 fusioncyclin C-related proteinhuman immunodeficiency virus type 1 (HIV-1) expression (elevated) 1
02
Mechanism of action
Inhibition of Cyclin-T1 (via CDK9 inhibition) blocks phosphorylation of RNA polymerase II, impeding transcription elongation and suppressing expression of critical genes including viral genes (notably HIV-1), oncogenes, and cell cycle-related genes
03
Biological functions
Regulation of transcription elongationCell cycle regulationPositive regulation of RNA polymerase IICofactor activity for viral transcription (especially HIV-1 Tat)
04
Disease associations
Infection (notably HIV-1 infection and replication)Cancer (tumor growth, overexpression implicated in some cancers)Other (roles in other viral life cycles, possible involvement in additional transcription-linked diseases)
05
Safety considerations
Inhibition of Cyclin-T1 may lead to global suppression of transcription, affecting rapidly proliferating cells (e.g., bone marrow, gastrointestinal epithelium); risks include cytopenias, gastrointestinal toxicity, and immunosuppression
06
Interacting drugs
There are no approved drugs that directly target Cyclin-T1 specifically, but certain inhibitors of the CDK9/Cyclin-T1 complex (such as **flavopiridol** and related **CDK9 inhibitors**) act on the complex as a whole.
07
Biomarkers
Cyclin-T1 levels or the activity of the CDK9/Cyclin-T1 complex may act as a biomarker for transcriptional activity (particularly in HIV-1-infected cells) and may serve as a pharmacodynamic marker for CDK9 inhibitor efficacy in research settings
Beyond the preview
Go deeper on Cyclin-T1 (CCNT1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclin-T1 (CCNT1).